Literature DB >> 25435739

Diagnosis and management of atypical hemolytic uremic syndrome in children: single centre experience.

Rashmi D Patel1, Aruna V Vanikar1, Manoj R Gumber2, Kamal V Kanodia1, Kamlesh S Suthar1, Himanshu V Patel2, Hargovind L Trivedi2.   

Abstract

Atypical hemolytic uremic syndrome (aHUS) although rare is the commonest cause of acute renal failure (ARF) in children and has poor prognosis. We present single centre experience of aHUS. Thirty six children (29 males, 7 females) with mean age, 7.9 years presented with ARF, 2 children also had tonic-clonic type convulsions. Their hematology examination revealed hemolytic anemia with s. creatinine (SCr), 5.54 mg/dl. Acute HUS was observed in 75 %, acute on chronic HUS in 19.4 % and patchy cortical necrosis (PCN) in 5.6 % biopsies. Mean 5.4 plasma exchanges (PE) were carried out. Supportive management of anti-hypertensives and prednisone was also given. Recovery end points were establishment of urine output, improvement of SCr and hematological profile. Hematology and renal function profile improved variably in all children, 5.6 % died, relapse was observed in 80.5 % over mean 70 days; 13.9 % children are doing well over mean follow-up of 268.8 days. Thus poor prognosis was observed in 86.1 % children. Children with acute on chronic HUS and PCN did not recover. Six children who recovered had acute HUS. aHUS in Indian children occurs at an older age of around 8 years and chronic/irreversible changes on histopathology examination are harbingers of poor prognosis. PE is life-saving however further research for developing strategies to improve long-term survival is needed.

Entities:  

Keywords:  Hemolytic uremic syndrome; Microangiopathic hemolytic anemia; Plasma exchange; Thrombotic thrombocytopenic purpura

Year:  2013        PMID: 25435739      PMCID: PMC4243409          DOI: 10.1007/s12288-013-0262-3

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  27 in total

1.  [Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia].

Authors:  C GASSER; E GAUTIER; A STECK; R E SIEBENMANN; R OECHSLIN
Journal:  Schweiz Med Wochenschr       Date:  1955-09-20

Review 2.  Atypical hemolytic-uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

3.  Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

Authors:  P N Lara; T L Coe; H Zhou; L Fernando; P V Holland; T Wun
Journal:  Am J Med       Date:  1999-12       Impact factor: 4.965

4.  Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): treatment outcome, relapses, prognostic factors. A single-center experience of 48 cases.

Authors:  J Dervenoulas; P Tsirigotis; G Bollas; V Pappa; N Xiros; T Economopoulos; M Pappa; S Mellou; A Kostourou; E Papageorgiou; S A Raptis
Journal:  Ann Hematol       Date:  2000-02       Impact factor: 3.673

5.  Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.

Authors:  W R Bell; H G Braine; P M Ness; T S Kickler
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

6.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

7.  United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange.

Authors:  N Bandarenko; M E Brecher
Journal:  J Clin Apher       Date:  1998       Impact factor: 2.821

8.  Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura: outcome with plasma exchange.

Authors:  A W Roberts; E A Gillett; S J Fleming
Journal:  J Clin Apher       Date:  1991       Impact factor: 2.821

9.  Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura.

Authors:  J J Byrnes; J L Moake; P Klug; P Periman
Journal:  Am J Hematol       Date:  1990-07       Impact factor: 10.047

10.  [Treatment of thrombotic thrombopenic purpura. Results of a multicenter randomized clinical study].

Authors:  P Henon
Journal:  Presse Med       Date:  1991-11-09       Impact factor: 1.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.